Evidence map›Paper›PMID 21565893›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2011

Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents.

Subash C Gupta, Ji Hye Kim, Ramaswamy Kannappan, Simone Reuter, Patrick M Dougherty, Bharat B Aggarwal

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04208334 (A Double-blind, Placebo-controlled Randomized Trial Phase II Evaluating the Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer), which is not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04208334 phase2completednot on this mapstarted 2020, after this paper: background citation

A Double-blind, Placebo-controlled Randomized Trial Phase II Evaluating the Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer

TypeinterventionalSponsorPhramongkutklao College of Medicine and HospitalRan2020 to 2021Enrolled20ConditionsCancer Cachexia, Head and Neck Cancer, Head and Neck NeoplasmsArmsCurcumin, Placebo
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 143 citations in OpenAlex.

  1. Trial
  2. Symptom clusters and network analysis in lung cancer patients receiving taxane-based chemotherapy: a comprehensive assessment using the CIPNAT multi-scale tool.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Metabolomics and its Applications in Cancer Cachexia.Frontiers in molecular biosciences · 2022
    Review
  12. Article
  13. A Perspective onJournal of immunology research · 2021
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights.International journal of molecular sciences · 2018
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Subash C GuptaCytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Ji Hye Kim
Ramaswamy Kannappan
Simone Reuter
Patrick M Dougherty
Bharat B Aggarwal
Cytokinetics (United States) · USThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
TARGETING NF-KB ACTIVATION IN REGULATION OF SYMPTOMS IN PATIENTS WITH MULTIPLEP01CA124787 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI REUBEN, JAMES MARTIN · 2008 to 2012
$10.6M
NCI NIH HHS CA-124787-01A2NCI NIH HHS CA-16672NCI NIH HHS P01 CA124787
6 · The paper itself

Abstract

Cancer is a disease characterized by dysregulation of multiple genes and is associated with symptoms such as cachexia, anorexia, fatigue, depression, neuropathic pain, anxiety, cognitive impairment, sleep disorders and delirium (acute confusion state) in medically ill patients. These symptoms are caused by either the cancer itself or the cancer treatment. During the past decade, increasing evidence has shown that the dysregulation of inflammatory pathways contributes to the expression of these symptoms. Cancer patients have been found to have higher levels of proinflammatory cytokines such as interleukin-6. The nuclear factor (NF)-κB is a major mediator of inflammatory pathways. Therefore, anti-inflammatory agents that can modulate the NF-κB activation and inflammatory pathways may have potential in improving cancer-related symptoms in patients. Because of their multitargeting properties, low cost, low toxicity and immediate availability, natural agents have gained considerable attention for prevention and treatment of cancer-related symptoms. How NF-κB and inflammatory pathways contribute to cancer-related symptoms is the focus of this review. We will also discuss how nutritional agents such as curcumin, genistein, resveratrol, epigallocatechin gallate and lycopene can modulate inflammatory pathways and thereby reduce cancer-related symptoms in patients.

Indexed as

Gene Expression RegulationSignal TransductionFoodHumansImmunologic FactorsInflammationNeoplasmsNF-kappa BImmunologic FactorsNF-kappa B

Identifiers

PMID21565893
PMCPMC3141285
OpenAlexW2038535468

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.